CytomX Therapeutics, Inc. (NASDAQ:CTMX) Given Average Recommendation of “Moderate Buy” by Analysts

CytomX Therapeutics, Inc. (NASDAQ:CTMX) has been assigned an average recommendation of “Moderate Buy” from the six brokerages that are presently covering the company, MarketBeat reports. Three investment analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $5.77.

CTMX has been the subject of several research reports. BMO Capital Markets upped their target price on CytomX Therapeutics from $3.25 to $3.59 and gave the stock a “market perform” rating in a research note on Thursday, May 9th. HC Wainwright reaffirmed a “neutral” rating on shares of CytomX Therapeutics in a report on Thursday, June 27th. Jefferies Financial Group upgraded shares of CytomX Therapeutics from a “hold” rating to a “buy” rating and lifted their target price for the stock from $2.50 to $8.00 in a research report on Monday, May 6th. Piper Sandler upgraded shares of CytomX Therapeutics from a “neutral” rating to an “overweight” rating and upped their price target for the company from $2.25 to $3.50 in a research report on Tuesday, May 28th. Finally, StockNews.com cut CytomX Therapeutics from a “buy” rating to a “hold” rating in a research note on Monday, June 17th.

Institutional Trading of CytomX Therapeutics

A number of institutional investors have recently modified their holdings of the company. AlphaMark Advisors LLC lifted its holdings in CytomX Therapeutics by 119.8% in the 4th quarter. AlphaMark Advisors LLC now owns 23,183 shares of the biotechnology company’s stock worth $36,000 after buying an additional 12,635 shares during the period. SG Americas Securities LLC bought a new position in shares of CytomX Therapeutics during the first quarter valued at approximately $57,000. Susquehanna Fundamental Investments LLC purchased a new stake in CytomX Therapeutics in the first quarter worth $124,000. Congress Park Capital LLC boosted its holdings in CytomX Therapeutics by 112.8% in the fourth quarter. Congress Park Capital LLC now owns 239,300 shares of the biotechnology company’s stock valued at $371,000 after acquiring an additional 126,850 shares in the last quarter. Finally, Acadian Asset Management LLC raised its holdings in CytomX Therapeutics by 1.7% in the 1st quarter. Acadian Asset Management LLC now owns 2,690,830 shares of the biotechnology company’s stock worth $5,863,000 after purchasing an additional 44,640 shares in the last quarter. 67.77% of the stock is currently owned by hedge funds and other institutional investors.

CytomX Therapeutics Stock Performance

CytomX Therapeutics stock opened at $1.32 on Friday. CytomX Therapeutics has a fifty-two week low of $1.04 and a fifty-two week high of $5.85. The firm’s fifty day moving average price is $1.95 and its 200-day moving average price is $1.87. The stock has a market cap of $102.85 million, a P/E ratio of 6.60 and a beta of 1.06.

CytomX Therapeutics (NASDAQ:CTMX) last issued its quarterly earnings results on Wednesday, May 8th. The biotechnology company reported $0.17 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.06) by $0.23. CytomX Therapeutics had a negative return on equity of 30.70% and a net margin of 13.87%. The firm had revenue of $41.46 million during the quarter, compared to analyst estimates of $23.40 million. On average, analysts predict that CytomX Therapeutics will post -0.14 earnings per share for the current year.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.